Premelle 2.5 Tablets / Sugar-coated
Oestrogens (conjugated), Medroxyprogesterone acetate
"0.625mg, 2.5mg"
WYETH MEDICA IRELAND
| Pack size | 28's Calendar Pack (14's Blister x 2) |
|---|---|
| Dispensing mode | POM |
| Source | IRELAND |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 40.50 AED |
Available as:
Indications
Premelle 2.5 Tablets / Sugar-coated is used for:
CONJUGATED EQUINE ESTROGENS
Conjugated equine estrogens (cees) are indicated for the following conditions: treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy associated with menopause; hypoestrogenism due to hypogonadism, castration or primary ovarian failure; palliation of metastatic breast cancer; palliation of advanced androgen-dependent carcinoma of the prostate; and for prevention of postmenopausal osteoporosis
MEDROXYPROGESTERONE ACETATE
Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, gnrh-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens
Conjugated equine estrogens (cees) are indicated for the following conditions: treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy associated with menopause; hypoestrogenism due to hypogonadism, castration or primary ovarian failure; palliation of metastatic breast cancer; palliation of advanced androgen-dependent carcinoma of the prostate; and for prevention of postmenopausal osteoporosis
MEDROXYPROGESTERONE ACETATE
Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, gnrh-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Oestrogens (conjugated), Medroxyprogesterone acetate :
Mechanism of Action
CONJUGATED EQUINE ESTROGENS
All estrogen products mimic the effects of endogenous estrogens in the body which are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (lh) and follicle stimulating hormone (fsh) through a negative feedback mechanism. Prior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in lh and fsh due to a lack of feedback control. This shift in hormone production is largely responsible for many of the symptoms experienced during and after menopause and includes hot flashes and other vasomotor symptoms, painful intercourse, vaginal dryness, and vulvovaginal atrophy. These symptoms are able to be reduced by replacing many of the hormones lost during and following menopause with synthetic or naturally occurring forms, in a therapy known as hormone replacement therapy (hrt)
MEDROXYPROGESTERONE ACETATE
Progestins diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (gnrh) from the hypothalamus and blunt the pre-ovulatory lh surge
All estrogen products mimic the effects of endogenous estrogens in the body which are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (lh) and follicle stimulating hormone (fsh) through a negative feedback mechanism. Prior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in lh and fsh due to a lack of feedback control. This shift in hormone production is largely responsible for many of the symptoms experienced during and after menopause and includes hot flashes and other vasomotor symptoms, painful intercourse, vaginal dryness, and vulvovaginal atrophy. These symptoms are able to be reduced by replacing many of the hormones lost during and following menopause with synthetic or naturally occurring forms, in a therapy known as hormone replacement therapy (hrt)
MEDROXYPROGESTERONE ACETATE
Progestins diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (gnrh) from the hypothalamus and blunt the pre-ovulatory lh surge
Note
Premelle 2.5 "0.625mg, 2.5mg" Tablets / Sugar-coated manufactured by WYETH MEDICA IRELAND. Its generic name is Oestrogens (conjugated), Medroxyprogesterone acetate. Premelle 2.5 is availble in United Arab Emirates.
Farmaco UAE drug index information on Premelle 2.5 Tablets / Sugar-coated is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.